Fig. 1. (A) Protocol used to generate EBHX cell lines. (B) Immunodetection of HOX11 protein (37 kD, arrow) in EBHX cell lines by immunoprecipitation of radiolabeled proteins with HOX11-specific antiserum. PGMD1, an IL-3–dependent myeloid progenitor line used as negative control; HX3, a bone marrow-derived HOX11-immortalized line used as positive control; EBHX, day 6 EBs generated from MSCV-HOX11 transduced ES cells; EBHX1, EBHX4, EBHX11, three EB-derived HOX11-immortalized cell lines. (C) Northern blot analysis with a neo probe demonstrating LTR-directed (4.0 kb) HOX11 mRNA (which contains downstream neo sequences) and pgk-directed (1.3 kb) neo mRNA in EBHX cell lines. CCE ES, wild-type ES cells; ES/HOX11, MSCV-HOX11 transduced ES cells; 3T3/HOX11, NIH3T3 fibroblasts transduced with the MSCV-HOX11 vector.
Fig. 1.

(A) Protocol used to generate EBHX cell lines. (B) Immunodetection of HOX11 protein (37 kD, arrow) in EBHX cell lines by immunoprecipitation of radiolabeled proteins with HOX11-specific antiserum. PGMD1, an IL-3–dependent myeloid progenitor line used as negative control; HX3, a bone marrow-derived HOX11-immortalized line used as positive control; EBHX, day 6 EBs generated from MSCV-HOX11 transduced ES cells; EBHX1, EBHX4, EBHX11, three EB-derived HOX11-immortalized cell lines. (C) Northern blot analysis with a neo probe demonstrating LTR-directed (4.0 kb) HOX11 mRNA (which contains downstream neo sequences) and pgk-directed (1.3 kb) neo mRNA in EBHX cell lines. CCE ES, wild-type ES cells; ES/HOX11, MSCV-HOX11 transduced ES cells; 3T3/HOX11, NIH3T3 fibroblasts transduced with the MSCV-HOX11 vector.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal